Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei

Malar J. 2016 Dec 7;15(1):588. doi: 10.1186/s12936-016-1632-8.

Abstract

Background: Due to the ability of the 8-aminoquinolines (8AQs) to kill different stages of the malaria parasite, primaquine (PQ) and tafenoquine (TQ) are vital for causal prophylaxis and the eradication of erythrocytic Plasmodium sp. parasites. Recognizing the potential role of cytochrome (CYP) 450 2D6 in the metabolism and subsequent hepatic efficacy of 8-aminoquinolines, studies were designed to explore whether CYP2D-mediated metabolism was related to the ability of single-dose PQ and TQ to eliminate the asexual and sexual erythrocytic stages of Plasmodium berghei.

Methods: An IV P. berghei sporozoite murine challenge model was utilized to directly compare causal prophylactic and erythrocytic activity (asexual and sexual parasite stages) dose-response relationships in C57BL/6 wild-type (WT) mice and subsequently compare the erythrocytic activity of PQ and TQ in WT and CYP2D knock-out (KO) mice.

Results: Single-dose administration of either 25 mg/kg TQ or 40 mg/kg PQ eradicated the erythrocytic stages (asexual and sexual) of P. berghei in C57BL WT and CYP2D KO mice. In WT animals, the apparent elimination of hepatic infections occurs at lower doses of PQ than are required to eliminate erythrocytic infections. In contrast, the minimally effective dose of TQ needed to achieve causal prophylaxis and to eradicate erythrocytic parasites was analogous.

Conclusion: The genetic deletion of the CYP2D cluster does not affect the ability of PQ or TQ to eradicate the blood stages (asexual and sexual) of P. berghei after single-dose administration.

MeSH terms

  • Aminoquinolines / administration & dosage
  • Aminoquinolines / pharmacology*
  • Animals
  • Antimalarials / administration & dosage
  • Antimalarials / pharmacology*
  • Chemoprevention / methods
  • Cytochrome P-450 CYP2D6 / deficiency
  • Cytochrome P-450 CYP2D6 / metabolism*
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Therapy / methods
  • Female
  • Malaria / drug therapy*
  • Male
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Plasmodium berghei / drug effects*
  • Primaquine / administration & dosage
  • Primaquine / pharmacology*
  • Treatment Outcome

Substances

  • Aminoquinolines
  • Antimalarials
  • tafenoquine
  • Cytochrome P-450 CYP2D6
  • Primaquine